The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11319-11328

  Song, Zhenguo ^a   Ren, He ^a   Gao, Song ^a   Zhao, Xiao ^a   Zhang, Huan ^a   Hao, Jihui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

HIF 1; MiR 191; Pancreatic cancer

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MICRORNA; MIRN191 MICRORNA, HUMAN; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER GRADING; CANCER STAGING; CELL HYPOXIA; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL HYPOXIA; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MICRORNAS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84927798840     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2452-5     Document Type: Article

References (36)

1. Sun W, Julie L, Huang HD, Shyy JY, Chien S. microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng. 2010;12:1–27.
2. Cecilia D, Simona G, Fabio M, et al. miR-210: more than a silent player in hypoxia. IUBMB Life. 2011;2(63):94–100.
3. Berezikov E, Furyev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120(1):21–4.
4. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136:586–91.
5. Song T, Zhang X, Wang C, et al. MiR-138 suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011;12(5):1307–11.
6. Srinivas V, David L, Anders K, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009;124(9):2236–42.
7. Jun Y, Kenoki O, Kazuhiro M, Jun Y, Kenoki O, Kazuhiro M, et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 2010;8(10):748–57.
8. Kizaka-Kondoh S, Tanaka S, Harada H, et al. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev. 2009;61(7–8):623–32.
9. Loscalzo J. The cellular response to hypoxia: tuning the system with microRNAs. J Clin Invest. 2010;120(11):3815–7.
10. Stephen YC, Joseph L. MicroRNA-210 a unique and pleiotropic hypoxamir. Cell Cycle. 2010;6(9):1072–83.
11. Rane S et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxic preconditioning in cardiac myocytes. Circ Res. 2009;104(7):879–86.
12. Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer[J]. Gut Liver. 2010;12(4):433–49. doi:10.5009/gnl.2010.4.4.433.
13. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival[J]. Int J Cancer. 2010;126(1):73–80. doi:10.1002/ijc.24687.
14. Liu R, Chen X, Du Y, et al. Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer[J]. Clin Chem. 2012;58(3):610–8. doi:10.1373/clinchem.2011.172767.
15. - △△ Ct method[J]. Methods. 2001;25(4):402–8.
16. Zhao T, Gao S, Wang X, Liu J, Duan Y, et al. Hypoxia-inducible factor-1α regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene. PLoS One. 2012;7(8):e43399. doi:10.1371/journal.pone.0043399.
17. Kulshreshthar R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia[J]. Mol Cell Biol. 2007;27:1859–67.
18. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia[J]. Blood. 2008;111(6):3183–9. doi:10.1182/blood-2007-07-098749.
19. Xi Y, Formentini A, Chien M, et al. Prognostic values of microRNAs in colorectal cancer[J]. Biomark Insights. 2006;2:113–21.
20. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci. 2006;103(7):2257–61. doi:10.1073/pnas.0510565103.
21. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias[J]. Proc Natl Acad Sci. 2004;101(32):11755–60. doi:10.1073/pnas.0404432101.
22. He Y, Cui Y, Wang W, et al. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma[J]. Neoplasia. 2011;13(9):841–53.
23. Sengupta S, Kim KS, Berk MP, et al. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion[J]. Oncogene. 2007;26:2894–901.
24. Piper M, Barry G, Hawkins J, et al. NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1[J]. J Neurosci. 2010;30(27):9127–39. doi:10.1523/JNEUROSCI.6167-09.2010.
25. Starnes LM, Sorrentino A, Ferracin M, et al. A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34(+) progenitors and CML cells[J]. Leukemia. 2010;24:1220–3. doi:10.1038/leu.2010.78.
26. Koli K, Ryynanen MJ, Keski-Oja J. Latent TGF-beta binding proteins (LTBPs)-1 and -3 coordinate proliferation and osteogenic differentiation of human mesenchymal stem cells[J]. Bone. 2008;43(4):679–88. doi:10.1016/j.bone.2008.06.016.
27. Chandramouli A, Simundza J, Pinderhughes A, et al. Choreographing metastasis to the tune of LTBP[J]. J Mammary Gland Biol Neoplasia. 2011;16:67–80. doi:10.1007/s10911-011-9215-3.
28. Soutar AK. Unexpected roles for PCSK9 in lipid metabolism[J]. Curr Opin Lipidol. 2011;22(3):192–6. doi:10.1097/MOL.0b013e32834622b5.
29. Grentzmann G, Ingram JA, Kelly PJ, et al. A dual-luciferase reporter system for studying recoding signals[J]. RNA. 1998;4(4):479–86.
30. Shi X, Su S, Long J, et al. MicroRNA-191 targets N-deacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803[J]. Acta Biochim Biophys Sin. 2011;43(11):849–56. doi:10.1093/abbs/gmr084.
31. Elyakim E, Sitbon E, Faerman A, et al. hsa- miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy[J]. Cancer Res. 2010;70:8077–87. doi:10.1158/0008-5472.CAN-10-1313.
32. Di Leva GD, Piovan C, Gasparini P, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status[EB/OL]. PLoS Genet. 2013;9(3):e1003311. doi:10.1371/journal.pgen.1003311.
33. Caramuta S, Egyhazi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma[J]. J Investig Dermatol. 2010;130:2062–70. doi:10.1038/jid.2010.63.
34. Hui AB, Shi W, Boutros PC, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues[J]. Lab Investig. 2009;89:597–606. doi:10.1038/labinvest.2009.12.
35. Shen J, DiCioccio R, Odunsi K, et al. Novel genetic variants in miR-191 gene and familial ovarian cancer[J]. BMC Cancer. 2010;10:47–56. doi:10.1186/1471-2407-10-47.
36. Wynendaele J, Bohnke A, Leucci E, et al. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity[J]. Cancer Res. 2010;70:9641–9. doi:10.1158/0008-5472.CAN-10-0527.